| Document |
Document Title |
|
WO/2024/101618A1 |
The present invention relates to cationic lipids and a manufacturing method therefor. More specifically, the present invention is concerned with cationic lipids that can easily form complexes with anionic drugs and thus are useful for dr...
|
|
WO/2024/102762A1 |
Described herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic ac...
|
|
WO/2024/094125A1 |
Provided herein are lipid compounds, e.g., a compound of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, e.g., a compound of Formula (I).
|
|
WO/2024/087584A1 |
Provided are a diester-based Gemini quaternary ammonium salt as well as a preparation method therefor and a use thereof. An obtained product may be used as a primary component of a fabric softener, and may also be used as a main bacteric...
|
|
WO/2024/078614A1 |
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and...
|
|
WO/2024/080821A1 |
The present specification relates to a compound and a molded body comprising same, the compound, represented by chemical formula 1, dissolving at room temperature in at least two of ether, toluene, and ethyl acetate.
|
|
WO/2024/070946A1 |
The present invention provides a composition for semiconductor devices which has the excellent ability to remove dry-etching residues and is more inhibited from causing the dissolution of tungsten and which, when works are treated therew...
|
|
WO/2024/058602A1 |
The present invention relates to a compound and a method for identifying impurities included therein.
|
|
WO/2024/052923A1 |
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
|
|
WO/2024/051825A1 |
Provided are a cationic lipid and a preparation method therefor, a lipid composition containing the cationic lipid, and an LNP-pharmaceutical composition containing the lipid composition and a preparation of the LNP-pharmaceutical compos...
|
|
WO/2024/032611A1 |
Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition comprising a therapeutic agent and/or a prophylactic agent such as RNA can be used for delivering the therapeutic agent a...
|
|
WO/2024/032754A1 |
Disclosed are a nitrogen-containing chain compound, a preparation method therefor, a composition containing said compound, and a use thereof. Provided is a nitrogen-containing chain compound as represented by formula (I) or a pharmaceuti...
|
|
WO/2024/027789A1 |
Disclosed are a cationic lipid compound as represented by formula (I) and composition for nucleic acid delivery, and a use. Also disclosed are a use of nano-lipid particles using said compound as a key component in the aspect of nucleic ...
|
|
WO/2023/239836A9 |
Disclosed herein are novel lipids, lipid nanoparticles and their uses for the transport of therapeutic agents to a subject, or for the treatment and/or prophylaxis of diseases in the subject.
|
|
WO/2024/019936A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2024/017254A1 |
The present application relates to an amino lipid compound having the following structural formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and use thereof as a component of a lipid nanoparticle preparation for ...
|
|
WO/2024/014430A1 |
The present invention addresses the problem of providing a method for producing an amino lipid compound that has improved yield in a carbonate esterification reaction and to provide an intermediate compound to be used in the abovemention...
|
|
WO/2024/010032A1 |
The purpose of the present invention is to provide an amino-group-containing polyfunctional (meth)acrylate composition that contains an amino-group-containing polyfunctional (meth)acrylate with high purity and that has a low coloration d...
|
|
WO/2023/250197A2 |
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, st...
|
|
WO/2023/246074A1 |
Provided in the present invention are a cationic lipid compound used for nucleic acid delivery, a composition and a use. The compound is as shown in the following formula (I). Further provided in the present invention are the use of the ...
|
|
WO/2023/249926A2 |
Fluorinated monomer compositions having the formula: A-L-Z (1), wherein A is a polymerizable group (e.g., a vinyl group); L is a bond or linking portion; Z is a zwitterionic moiety or a zwitterionic precursor moiety containing a protecti...
|
|
WO/2023/246747A1 |
Provided in the present invention are a cationic lipid compound and a composition for delivery of a nucleic acid, and the use. The compound is represented by the following formula (I). Further provided in the present invention are the us...
|
|
WO/2023/235976A1 |
A polycation carrier particle obtained by the polymerization of a multiacrylate monomer with one or more hydrophilic monomers to form crosslinks. The polycation carrier particle has a net positive electric charge. The multiacrylate monom...
|
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/229293A1 |
The present invention relates a bicycle derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. Found to have ACC inhibitory activity involved in the inhibitory mecha...
|
|
WO/2023/202554A1 |
Disclosed are a chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I), and the definition of each group is given in the description...
|
|
WO/2023/186041A1 |
Disclosed are a cationic lipid compound, and a preparation method therefor and use thereof. Hydroxyl is introduced into the cationic lipid compound at the head, and meanwhile, the overall structure is similar to a cone with a small head ...
|
|
WO/2023/186167A1 |
Disclosed is a cationic lipid having the following general formula (I), wherein A, B, C, and D are each as defined in the description. Also disclosed are a liposome and a lipid nanoparticle containing the cationic lipid, and use of the c...
|
|
WO/2023/186171A1 |
Disclosed is a cationic lipid having the following general formula (I), wherein A, B, C, and D are each as defined in the description. Also disclosed are a liposome and a lipid nanoparticle comprising the cationic lipid, and use of the c...
|
|
WO/2023/188830A1 |
The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group r...
|
|
WO/2023/179463A1 |
The present invention relates to a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which relate to the technical field of medical biology. The problem of there being an urgent need...
|
|
WO/2023/179462A1 |
Disclosed in the present invention are a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which solve the problem of there being an urgent need to develop cationic lipids with high ...
|
|
WO/2023/179497A1 |
The present invention belongs to the field of gene drug delivery, and particularly relates to a lipid compound, a lipid carrier based on the lipid compound, a nucleic acid lipid nanoparticle composition and a pharmaceutical formulation. ...
|
|
WO/2023/173203A1 |
Provided herein is a method for a method for producing an ionizable amino lipid, or a pharmaceutically acceptable salt thereof, the method comprising a nucleophilic displacement of a leaving group L in a compound of Formula (II), wherein...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/160702A1 |
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a ...
|
|
WO/2023/164544A2 |
Provided herein, inter alia, novel ionizable cationic lipids, lipid nanoparticles comprising the novel ionizable cationic lipids and methods of using said nanoparticles.
|
|
WO/2023/143601A1 |
Provided in the present invention are a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. In the present invention, a specific cationic lipid is selected for preparing a lipid nanoparticle mRNA vaccine, which is foun...
|
|
WO/2023/143600A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipi...
|
|
WO/2023/143591A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. It is found that the lipid nanoparticle mRNA vaccine prepared in the present invention by selecting a specific cationic lipid has bet...
|
|
WO/2023/141624A1 |
Ionizable lipids and lipid nanoparticles comprising ionizable lipids are provided herein. Also provided are methods for making and using the lipid nanoparticles for delivery to a cell one or more payload agents, including polypeptides, m...
|
|
WO/2023/134325A1 |
A lipid compound, a composition containing same, and a use, the lipid compound being prepared by means of a ring-opening reaction of organic amine and glycidyl ester, and the structure not containing free amino groups. The lipid compound...
|
|
WO/2023/136689A1 |
The present invention relates to a novel ionizable lipid containing a biodegradable ester bond. The ionizable lipid containing an ester bond, according to the present invention, stably delivers an anionic drug when prepared into lipid na...
|
|
WO/2023/121971A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2023/121965A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2023/113456A1 |
The present invention relates to a compound capable of degrading a target protein by using ubiquitination, and provides a compound having a targeted protein binding moiety (TBM) structure, which binds to a target protein or polypeptide, ...
|
|
WO/2023/113457A1 |
The present invention relates to a compound capable of degrading a target protein by using ubiquitination, and provides a compound having a targeted protein binding moiety (TBM) structure, which binds to a target protein or polypeptide, ...
|
|
WO/2023/112939A1 |
A method for purifying a composition that comprises a step for dissolving the composition containing a compound represented by formula(1) [in formula (1): R1 represents -N(R2)-R2 (wherein R2 represents a C1-C4 alkyl group); R3 and R4 rep...
|
|
WO/2023/114188A1 |
Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions...
|
|
WO/2023/103734A1 |
Disclosed in the present invention are a cannabidiol derivative, a preparation method therefor and an application thereof, particularly an application in preventing and treating nervous system diseases (such as Parkinson's disease). The ...
|
